Laila Abdullah will be presenting the paper on Friday (1/28/2011) at 4:00 PM in Roskamp Institute.
Title: Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis
PNAS July 6, 2010 vol. 107 no. 27 12233-12238
Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.
The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949
Share on Facebook
Comments Off
Chris Mayer will be presenting the paper on Friday (1/21/2011) at 4:00 PM in Roskamp Institute.
Title: The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies
Pharmacol Res. 2010 Dec 14. [Epub ahead of print]
Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.
The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949
Share on Facebook
Comments Off
Patients Like Me Trial Awareness V1
Ono-RRMS-U006
One Pill. Once A Day. A clinical trial for those with Relapsing-Remitting Multiple Sclerosis.
Imagine MS treatment without the injections. Without the subsequent pain, bruising and burning. Doctors specializing in MS treatment are currently researching alternatives that could make treatment a whole lot easier to take.
About the DreaMS research study
The DreaMS clinical trial is evaluating the effectiveness and safety of an oral investigational medication (taken by mouth) for RRMS. Researchers are also interested in learning if the investigational medication has fewer side effects and is a less-invasive alternative to the injectable RRMS medications currently available.
The study is evaluating 3 different doses of the study medication to inactive placebo. Study participants have a 3 in 4 (75%) chance of receiving the investigational medication versus inactive placebo.
To qualify for the study you must:
- Be 18-55 years of age
- Have a medical diagnosis of relapsing-remitting MS
- Have had your first MS symptoms within the past 12 years
The study staff will determine your full eligibility. If you take part, all study-related care is provided at no cost to you including study visits, physical exams, diagnostic tests, and study medication/placebo. Compensation is also provided if you take part.
To learn more and find out if you pre-qualify for the DreaMS study, please visit www.DreamsClinicalTrial.com.
Share on Facebook
Comments Off
Helena Chaytow will be presenting the paper on Friday (1/7/2011) at 4:00 PM in Roskamp Institute.
Title: Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury
Brain Res. 2010 Nov 11;1360:177-92. Epub 2010 Sep 15.
Journal Club is held every Friday. For change in schedule please check our Twitter account or Facebook page.
The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease. For more information, please call (941)752-2949
Share on Facebook
Comments Off